Co-Authors
This is a "connection" page, showing publications co-authored by MARIA E CABANILLAS and MARIA KRISTINE GULE-MONROE.
Connection Strength
1.374
-
Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2024 Mar; 34(3):336-346.
Score: 0.239
-
Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head Neck. 2021 01; 43(1):E7-E12.
Score: 0.191
-
Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors. Thyroid. 2020 09; 30(9):1288-1296.
Score: 0.184
-
Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2019 08; 29(8):1036-1043.
Score: 0.175
-
Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma. JCO Precis Oncol. 2018 Dec; 2.
Score: 0.167
-
Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer. 2018 07 11; 6(1):68.
Score: 0.162
-
Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Thyroid. 2018 01; 28(1):79-87.
Score: 0.156
-
Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series. Thyroid. 2023 01; 33(1):129-132.
Score: 0.055
-
Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in?sporadic medullary thyroid carcinoma. Surgery. 2020 01; 167(1):80-86.
Score: 0.044